FIRST

1ST Biotherapeutics is a clinical-stage biotechnology company focused on developing first-in-class small molecule therapeutics for neurodegenerative diseases, immuno-oncology, and rare diseases. Headquartered in South Korea, the company leverages a proprietary genomic-based target discovery platform to identify novel mechanisms for disease modification. Its lead programs include FB-101, a brain-penetrant c-Abl inhibitor for Parkinson's disease, and FB-849, an HPK1 inhibitor for advanced solid tumors. 1ST Biotherapeutics maintains a robust R&D network across Korea, China, and the United States, supported by significant venture capital investment.